Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs have been updated August 1, 2023:
Effective September 1, 2023:
- Substrate Reduction Therapy
- Skyclarys
- Daybue
- Joenja
- Biologic Immunomodulators
- Isturisa
- Parathyroid Hormone Analog Osteoporosis
- IL-4 Inhibitor
- IL-5 Inhibitors
- Xolair
- Elagolix/Relugolix
- Oxybate
Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.
To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization.
If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.